Document is current
Any future updates will be listed below
-
Authors
Tiwary, Kanishka
Lahusen, Anton
Inaas, Syeda
Beitzinger, Bastian
Schmid, Roman
Harms, Mirja
Hauff, Stefanie
Arnold, Frank
Walter, Karolin
Alcala, Sonia
Hahn, Stephan
Heßmann, Elisabeth
Kleger, Alexander
Azoitei, Ninel
Seufferlein, Thomas
Sainz, Bruno Jr.
Münch, Jan
Lindén, Mika
Hermann, Patrick C.
-
Funding
Funding for this research was provided by:
Universität Ulm
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 8 April 2026
First Online: 16 April 2026
Competing interests
: M.H., and J.M. are co-inventors of pending and issued patents that claim to use EPI-X4 (ALB408-423) and derivatives for the therapy of CXCR4-associated diseases. All other Authors have no competing interests to declare.
: Not applicable.
: The patient derived xenograft used in this study were obtained under the Material Transfer Agreement with Spanish National Cancer Center (CNIO), Madrid, Spain (Reference no. I409181220BSMH and I405271505PHMH) followed by the ethics committee approval of Ulm University (161/15 – The role of circulating cancer stem cells in EMT and Metastasis). The patient derived organoids were obtained by the biobank of the University Hospital of Ulm followed by the ethics committee approval of Ulm University (72/2019: PDAC Liver Metastasis) and (67/2019: human tissue and blood).
